Risk of sales restrictions and performance impact arising from compliance incidents in 2025
First written in FY2026. 5 of 6 entries say "Materialised", first in 2026-05-08. Latest entry: 2026-07-30.
No other company in this theme has enough history to compare yet.
- 2026-07-30MaterialisedEarnings
「In Japan's artificial joint market, the impact of the media reports continued in the first quarter, following the fourth quarter of the previous fiscal year. Some medical institutions were seen declining to adopt our products. As a result, the number of total hip arthroplasty (THA), bipolar hip arthroplasty (BHA) and total knee arthroplasty (TKA) cases declined, and sales decreased from the same quarter of the previous fiscal year.」
Hospitals' decisions not to adopt the products and the resulting decline in cases due to the media reports continued into the first quarter, with domestic artificial joint sales declining 16.6% year on year. - FY2026MaterialisedAnnual report
「In the domestic artificial joint market, from the fourth quarter onward, some healthcare institutions declined to adopt the Company’s products due to the impact of the reported incident, resulting in a decline in the number of cases won.」
Following the reported incident in Japan, some healthcare institutions actually declined to adopt the Company’s products, resulting in fewer cases. The risk disclosures also explain that inappropriate conduct by officers or employees, or violations of laws and regulations, could result in administrative guidance, sales restrictions and lower revenue.